Clear cell renal cell carcinoma with prominent microvascular hyperplasia: Morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 16 11 2021
accepted: 17 11 2021
pubmed: 1 12 2021
medline: 23 3 2022
entrez: 30 11 2021
Statut: ppublish

Résumé

Clear cell renal cell carcinoma (CCRCC) is well known for intratumor heterogeneity. An accurate mapping of the tumor is crucial for assessing prognosis, and perhaps this can be linked to potential success/failure of targeted therapies. We assembled a cohort of 7 CCRCCs with prominent vasculature and microvascular hyperplasia (ccRCCPV), resembling those seen in high grade gliomas. A control group of classic CCRCC with no variant morphologies was also included. Both groups were analyzed for clinicopathologic, morphologic, immunohistochemical, and molecular genetic features. No statistically significant differences in mRNA expression of studied genes between the two groups were found. Using NGS panel Trusight Oncology 500 (TSO500), only one clinically significant gene mutation, VHL c.263G > A, p. (Trp88Ter), was found. TMB (Tumor Mutation Burden) and MSI (MicroSatellite Instability) were low, and no copy number variations (CNVs) were detected in the study cohort. Prominent microvascular hyperplasia in CCRCC is a rare phenomenon. From molecular genetic point of view, these tumors do not appear to be different from classic CCRCC. Prognostically, they also demonstrated similar clinical behaviors.

Identifiants

pubmed: 34847388
pii: S1092-9134(21)00171-4
doi: 10.1016/j.anndiagpath.2021.151871
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151871

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Reza Alaghehbandan (R)

Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

Rinë Limani (R)

Institute of Pathology, Faculty of Medicine, Hospital and University Clinical Services of Kosovo, Pristina, Kosovo.

Leila Ali (L)

Department of Pathology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.

Joanna Rogala (J)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic; Department of Pathology, Regional Specialist Hospital, Wroclaw, Poland.

Tomas Vanecek (T)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Petr Steiner (P)

Bioptic Laboratory, Ltd, Molecular Pathology Laboratory, Plzen, Czech Republic.

Veronika Hajkova (V)

Bioptic Laboratory, Ltd, Molecular Pathology Laboratory, Plzen, Czech Republic.

Levente Kuthi (L)

Department of Pathology, University Hospital Szeged, Szeged, Hungary.

Maryna Slisarenko (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Kvetoslava Michalova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Kristyna Pivovarcikova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Milan Hora (M)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Tomas Pitra (T)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Michal Michal (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic.

Ondrej Hes (O)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Plzen, Czech Republic. Electronic address: hes@biopticka.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH